About Scil Proteins
Scil Proteins is a company based in Halle (Germany) founded in 1999 was acquired by Wacker Chemie in June 2014. Scil Proteins has raised $32.07 million across 1 funding round from investors including Wacker Chemie and BioNet Pharma. The company has 54 employees as of December 31, 2021. Scil Proteins operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Halle, Germany
- Employees 54 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Navigo Proteins Gmbh
-
Annual Revenue
$56.91 K (USD)2as on Dec 31, 2015
-
Net Profit
-$3.93 M (USD)-16as on Dec 31, 2015
-
EBITDA
Not available
-
Total Equity Funding
$32.07 M (USD)
in 1 rounds
-
Latest Funding Round
$32.07 M (USD), Series C
Jun 01, 2010
-
Investors
Wacker Chemie
& 1 more
-
Employee Count
54
as on Dec 31, 2021
-
Acquired by
Wacker Chemie
(Jun 01, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Scil Proteins
Scil Proteins has successfully raised a total of $32.07M through 1 strategic funding round. The most recent funding activity was a Series C round of $32.07 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Scil Proteins
Scil Proteins has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Wacker Chemie and BioNet Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Develops and licenses pharmaceutical programs for various indications through partnerships.
|
Locked | Locked | Locked | |
|
Silicones, polymers, and bio-solutions are manufactured for various industries.
|
Locked | Locked | Locked |
Investor details for Scil Proteins
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scil Proteins
Investment portfolio details for Scil Proteins
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Scil Proteins
Detailed financials for Scil Proteins
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scil Proteins Comparisons
Peer comparison for Scil Proteins
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Scil Proteins
Scil Proteins operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Scil Proteins
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scil Proteins
Complete news archive for Scil Proteins
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scil Proteins
Scil Proteins was founded in 1999 and raised its 1st funding round 11 years after it was founded.
Scil Proteins is headquartered in Halle, Germany. It is registered at Halle, Sachsen-anhalt, Germany.
Scil Proteins is a funded company, having raised a total of $32.07M across 1 funding round to date.
As of Dec 31, 2021, the latest employee count at Scil Proteins is 54.
Annual revenue of Scil Proteins is $56.91K as on Dec 31, 2015.
Scil Proteins was established in 1999 in Halle, Germany, within the biotechnology sector. Affilin-based proteins, derived from human scaffolds, are engineered using a proprietary modular platform for therapeutic and non-therapeutic purposes. Operations focus on developing drug conjugates, multi-specific binding molecules, and ligands for partners in pharmaceuticals, biotech, and life sciences. Full ownership is maintained by BioNet Ventures.
Scil Proteins's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Scil Proteins has 2 investors. Key investors include Wacker Chemie, and BioNet Pharma.